This study aimed to evaluate etrolizumab as a treatment for patients with moderate to severe ulcerative colitis who are naive to TNF inhibitors.
About this study
The purpose of this study was to determine whether etrolizumab is:
- A safe and effective treatment in patients with moderate to severe active ulcerative colitis that have previously had an unsuccessful response to treatment with immunosuppressants (also known as TNF inhibitors – medications that reduces the activation or efficacy of the immune system) such as azathioprine, 6-mercaptopurine, or methotrexate and/or corticosteroids
- More effective than adalimumab in treating ulcerative colitis
Adalimumab is approved by the Therapeutic Goods Administration in Australia for use in ulcerative colitis.
Enrolment is closed for this study.
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.